Brexit: What does it mean for comparator trial medicines?
Pilatus CS, along with its parent company Orifarm, have been working to minimise the implications of Brexit for our customers. Pilatus, along with its sister company UL Global Pharma, have a well-established, global network of suppliers and our own presence in the US and Europe, so we are not limited to just one market, supply route or supplier.
With three European GDP approved storage and distribution depots, our infrastructure enables us to offer continuity of supply for comparator and commercial drugs sourced for Clinical Trials in both the UK and Europe.
Our group of companies also ensure our stock holding capacity has been increased to align with DHSC guidelines and across the Orifarm network, we are operating a one vision policy, putting you and your patients centre of all of our decisions.